AFMD

Affimed NV Stock Price

3.31
0.10 (3.12%)
Upgrade to Real-Time
Afterhours (Closed)
3.31
Best deals to access real time data!
Big Cap Pro
Monthly Subscription
for only
$52.04
Small Cap Basic
Monthly Subscription
for only
$33.03
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
$67.09
VAT not included
Company Name Stock Ticker Symbol Market Type
Affimed NV AFMD NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.10 3.12% 3.31 20:00:00
Close Price Low Price High Price Open Price Previous Close
3.31 3.18 3.33 3.24 3.21
Bid Price Ask Price Spread News
3.12 3.75 0.63 - -
Stock Trades Traded Volume VWAP Dollar Volume Average Volume 52 Week Range
2,449 1,716,685 $ 3.27 $ 5,615,602 705,889 1.42 - 4.91
Last Trade Time Type Quantity Stock Price Currency
17:33:21 formt 13,621 $ 3.31 USD

Affimed NV Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 279.67M 84.49M 80.94M $ 24.00M $ - -0.56 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - 0.00% - -

more financials information »

Affimed NV News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical AFMD Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week3.503.5453.133.29588,263-0.19-5.43%
1 Month3.323.803.133.48540,357-0.01-0.3%
3 Months3.814.113.073.55798,599-0.50-13.12%
6 Months2.264.911.753.551,064,3001.0546.46%
1 Year2.824.911.422.99969,8530.4917.38%
3 Years2.057.351.153.39880,2831.2661.46%
5 Years6.558.261.153.36622,694-3.24-49.47%

Affimed NV Description

Affimed NV is a clinical-stage biopharmaceutical company. The company is engaged in discovering and developing targeted cancer immunotherapies. Its product candidates are being developed in the field of immuno-oncology, which represents an approach to cancer treatment that seeks to harness the body's immune defenses to fight tumor cells. The company is also developing single and combination therapies to treat cancers and other life-threatening diseases. Geographically, it derives a majority of revenue from the United States and also has a presence in Europe and Germany.


Your Recent History
NASDAQ
AFMD
Affimed NV
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.